ELTX · Elicio Therapeutics, Inc. · Executive Compensation
$2.05
-0.06 (-2.84%)
At close · Sep 11
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”View the 10-Q filed Aug 13, 2026
Market Cap
$53.88M
Shares
26.28M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Connelly | President, Chief Executive Officer, and Director | $2,036,441 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $926,452 |
| Peter DeMuth | Chief Scientific Officer | $866,671 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | former Chief Executive Officer, President, and Chairman of the Angion Board | $2,429,275 |
| Jennifer J. Rhodes | former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | $1,365,859 |
| Brian Piekos | former Chief Financial Officer and Treasurer | $878,755 |
| Robert Connelly | President, Chief Executive Officer, and Director | $678,300 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $673,821 |
| Peter DeMuth | Chief Scientific Officer | $502,636 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | former Chief Executive Officer, President, and Chairman of the Angion Board | $1,518,849 |
| Robert Connelly | President, Chief Executive Officer, and Director | $1,256,040 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $1,162,356 |
| Jennifer J. Rhodes | former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | $773,653 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | M.D., President and Chief Executive Officer and Chairman of the Board | $2,539,199 |
| Itzhak D. Goldberg | M.D., Executive Chairman and Chief Scientific Officer | $1,247,881 |
| John F. Neylan | M.D., Executive Vice President, Chief Medical Officer and Head of Research | $1,232,513 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | M.D., President and Chief Executive Officer and Chairman of the Board | $1,394,398 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Preetam Shah, Ph.D., M.B.A. | Principal Accounting Officer | Appointed | 2025-03-24 |
| Preetam Shah, Ph.D., M.B.A. | Principal Financial Officer | Appointed | 2025-03-24 |
| Preetam Shah, Ph.D., M.B.A. | Chief Strategy and Financial Officer | Appointed | 2025-03-24 |
| Robert Connelly | Principal Accounting Officer and Principal Financial Officer | Appointed | 2024-10-17 |
| Brian Piekos | Chief Financial Officer and Treasurer | Resigned | 2024-08-30 |
Key facts
CIK
1601485
CUSIP
28657F103
13F (30d)
19 filings
19 filers
Visit website
Investor relations